Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients

Purpose: Evaluation of serum TNFalpha receptor 1 (p55) and 2 (p75) concentrations preoperatively in patients with ovarian masses.

Methods: Estimation by ELISA assay in 51 women with ovarian cancer and 16 healthy controls. Mean values and correlations with CA-125, tumour volume index, morphological score, pathological finding and cytoreduction were estimated.

Results: Mean concentrations of p55 and p75 in cancer patients were 2006 +/- 1030 pg/ml and 2849 +/- 1092 pg/ml, respectively, whereby for controls 1323 +/- 291 pg/ml and 2386 +/- 475 pg/ml, respectively. The area under the ROC curve for CA-125, p55 and p75 for cancer (FIGO Stages I-IV) were: 0.85 (95% CI 0.75-0.92), 0.73 (95% CI 0.60-0.83) and 0.65 (95% CI 0.50-0.77), respectively. Serum p55 correlated with morphological ultrasound score and CA-125 but not with FIGO stage, tumour grade or tumour volume index. No correlations of p75 with these parameters were observed.

Conclusion: Estimation of p55 and p75 provide little information in ovarian cancer patients and have poor detecting power.

TNFa; Receptor 1; Receptor 2; Ovarian; Cancer; Tumour marker

[1] Chen G., Goedde! D.V.: "TNF-R l signaling: a beautiful pathway". Science, 2002, 296, 1634.

[2] Medvedev A., Espevik T., Ranges T. et al.: "Distinct roles of two tumor necrosis factor (TNF) receptors in modultaing TNF and lymphotoxin a effects". J. Biol. Chem., 1996, 271, 9778.

[3] Kost E.R., Herzog T.J., Adler L.M. et al.:'The role of tumor necrosis factor receptors in tumor necrosis factor-a-mediated cytolysis of ovarian cancer cell lines". Am. J. Obstet. Gynecol., 1996, 174, 145.

[4] Bigda J., Beletsky I., Brakebush C. et al.: "Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity". J. Exp. Med., 1994, 180, 445.

[5] Tartaglia A.T., Pennica D., Goedddel D.V.: "Ligand passing: the 75kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor". J. Biol. Chem., 1993, 268, 18542.

[6] Olsson L, Galanga T., Bullberg U. et al.: "Tumor necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy". Eur. Cytokine Netw., 1993, 4, 169.

[7] Bazzoni F., Beutler B., Flier J. et al.: "The tumor necrosis factor ligand and receptor families". N Engl. I. Med., 1996, 334, 1717.

[8] Brockhaus M., Schoenfeld HJ., Schlager E.J. et al.: "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies". Proc. Natl. Acad. Sci., 1990, 87, 3127.

[9] Sancho-Tello M., Marcink比wicz J.L., Justice W.M. et al.: "Reduction of tumor necrosis factor-a bioactivity by a human ovarian epithelial cancer cell line in vitro". Am. I. Ohstet. Gynecol., 1995, 173, 1470.

[10] Myamon E., Ghezzi F., Edwin S.S. et al.: "The tumor necrosis factor a and its soluble receptor profile in term and preterm partuition". Am. J. Ohstet. Gynecol., 1999, 181, 1142.

[11] Gadducci A., Ferdeghini M., Castellani C. et al.: "Serum levels of Tumor Necrosis Factor (TNF), soluble receptors for TNF (55- and 75-kDA sTNFr) and soluble CD14 (sCD14) in epithelial ovarian cancer". Gynecol. Oncol., 1995, 58, 184.

[12] Naylor M.S., Stamp G.W.H., Foulkes W.D. et al.:'Tumor necrosis factor and its receptors in human ovarian cancer - potential role in disease progression". J. Clin. Invest., 1993, 91, 2194.

[13] Onsrud M., Shabana A., Austgulen R. et al.: "Companson between soluble Tumor Necrosis Factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer". Gynecol. Oncol., 1995, 57, 183.

[14] Ferrazzi E., Zanetta G., Dordoni D. et al.:'Transvaginal ultrasonographic characterisation of ovarian masses: comparison of five scoring system in a multicenter study". Ultrasound Ohstet. Gynecol., 1997, 10, 192.

[15] Metz C.E., Herman B.A., Roe C.A.: "Statistical comparison of two ROC curve estimates obtained from partially-paired datasets". Med. Dec is. Making, 1998, 18, 110.

[16] Topalak 0., Saygili U., Soyturk M. et al.: "Serum, pleural effusion and ascites CA l 25 levels in ovarian cancer and nonovarian benign and malignant disease: a comparative study". Gynecol. Oneal., 2002, 85, 108.

[17] Aslam N., Tailor A., Lawton F. et al.: "Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer". B.J.O.G., 2000, 107, 1347.

[18] Menon U., Talaat A., Rosenthal A.N. et al.: "Performance of ultrasound as a second line test to serum CA 125 in ovarian cancer screening". B.J. O. G., 2002, 107, 165

[19] Sjovall K., Nilsson B., Einhorn N.: "The significance of serum CA 125 elevation in malignant and nonmalignant disease". Gynecol. Oneal., 2002, 85, 175.

[20] Berek J.S., Bast R.C.: "Ovarian cancer screening". Cancer, 1995, 76, 2092.

[21] Markowska J., Wilkoszarska J.: "The value of CA 125 levels in serum, peritoneal fluid and tumor in women with ovarian cancer". Gin. Pol., 1996, 67, 352.

[22] Viac J., Vincent C., Palacio S. et al.: "Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels". Eur. J. Cancer, 1996, 32, 447.